Research Peptide FAQs | CoreVionRX

A Certificate of Analysis is a batch-specific laboratory document that records the results of independent testing on a specific production lot. For research peptides, a COA should include: HPLC purity percentage with the chromatogram, mass spectrometry identity confirmation, the lot or batch number, and the testing laboratory’s identification. The lot number is what separates a genuine COA from a marketing template — it ties the document to the specific batch you received. CoreVionRX provides a lot-specific COA with every order. If a supplier provides a generic COA without a specific lot number, that document cannot be used to verify your actual batch.

HPLC (High-Performance Liquid Chromatography) separates a sample’s components and measures the relative area of each peak in the chromatogram. The purity percentage represents the target compound’s peak area as a fraction of all detected peaks. For research peptides, ≥98% purity by HPLC is the accepted minimum for serious laboratory use. At this threshold, less than 2% of the vial contents are impurities, synthesis byproducts, or degradation products. Anything below 95% introduces meaningful contamination risk that can confound research results. The chromatogram — not just the percentage — should appear on your COA. A single dominant peak with no significant satellite peaks confirms the result. Our blog covers why HPLC purity alone isn’t the full picture for certain research applications.

HPLC confirms relative purity — that the target compound is the dominant component — but it does not confirm molecular identity. A compound could pass HPLC testing at 99% purity and still be the wrong molecule if labeling or synthesis errors occurred. Mass spectrometry measures the molecular mass of the compound directly and compares it against the expected value for the specific peptide. The combination of ≥98% HPLC purity plus mass spec identity confirmation is the standard that meaningful peptide research requires. CoreVionRX requires both for every compound in the catalog.

Endotoxins are lipopolysaccharides from the cell walls of gram-negative bacteria. They are biological contaminants, not chemical impurities — which means they do not appear in HPLC analysis. A compound can be 99% pure by HPLC and still carry biologically significant endotoxin levels. In cell-based assays and certain in vivo models, endotoxin contamination can independently activate inflammatory pathways and produce results that have nothing to do with the peptide being studied. For research applications involving immune cells, cytokine measurement, or any inflammatory endpoint, endotoxin-specific testing (LAL assay) is a separate verification step beyond standard HPLC and mass spec. We cover this in detail in our post on endotoxin testing in research peptides.

The chromatogram is a graph with time on the x-axis and UV absorbance on the y-axis. Each peak represents a component detected in the sample. For a high-purity research peptide, you should see one dominant peak (the target compound) at the expected retention time, with the baseline flat between any smaller peaks. Key things to evaluate: the height and sharpness of the main peak (tall and sharp is better than broad or shouldered), the size of any satellite peaks relative to the main peak (anything above 1% of total area is meaningful), and baseline noise levels (a clean baseline indicates a well-controlled separation). The purity percentage is calculated from peak areas — the main compound peak area divided by the sum of all peak areas.

CoreVionRX uses third-party independent testing conducted by external laboratories with no financial interest in the result. In-house testing — where the same company that synthesizes the compound also tests it — creates a conflict of interest that makes the results less credible for serious research use. Our COAs identify the testing laboratory. Every batch is tested before release. If a batch does not meet the ≥98% HPLC purity threshold with confirmed mass spectrometry identity, it does not go into the catalog.

Store lyophilized (freeze-dried) peptides at −20°C in the original sealed vial, protected from light and moisture. Lyophilized peptides are stable at this temperature for 24 months or longer in most cases. Do not open the vial until ready to reconstitute — moisture in the air can begin degrading the powder even before you add solvent. If bringing a vial from the freezer to the bench, allow it to reach room temperature before opening to prevent condensation from forming on the powder. Our peptide storage guide covers compound-specific storage considerations in detail.

Bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) is the standard reconstitution solvent for most research peptides. The benzyl alcohol preservative allows safe multi-dose access from a single vial, making it appropriate for protocols that require repeated preparation. Sterile water without preservative is single-use only — once the septum is punctured, the remaining volume should not be reused. Regular saline introduces sodium ions that can affect certain assay systems. For most compounds in the CoreVionRX catalog, bacteriostatic water is the correct choice. Our complete bacteriostatic water guide covers compatibility, pH, and multi-dose storage in detail. We also carry bacteriostatic water for this purpose.

The formula is straightforward: divide the peptide mass (in mg) by your target concentration (in mg/mL) to get the required water volume in mL. Example: a 5mg vial at a target concentration of 2mg/mL requires 2.5mL of bacteriostatic water. The choice of target concentration depends on the injection or application volume your protocol requires — small-volume protocols work better with higher concentrations. Use the peptide reconstitution calculator to eliminate manual calculation errors for any combination of vial size and target concentration.

Store reconstituted peptide solutions at 2–8°C (refrigerator temperature). Bacteriostatic water’s benzyl alcohol preservative maintains sterility across multiple needle entries for approximately 28 days. However, the peptide itself degrades at a different rate regardless of sterility — most research protocols use reconstituted solutions within 30 days. Do not freeze reconstituted solutions as a routine practice; most peptides degrade faster through repeated freeze-thaw cycles than through refrigerated storage. If your protocol spans multiple weeks, consider preparing individual aliquots from lyophilized stock (before any reconstitution) and reconstituting each aliquot fresh at the time of use. See our complete reconstitution guide for step-by-step protocol and troubleshooting.

Cloudiness after reconstitution most commonly indicates one of three things: incomplete dissolution (the peptide hasn’t fully dissolved — swirl gently and wait 5–10 minutes), aggregation from mechanical disruption (shaking or directing the water jet directly onto the powder can cause irreversible clumping — this is why slow wall-injection technique matters), or a concentration that exceeds the peptide’s solubility limit for that solvent. GHK-Cu is an exception — it produces a light blue solution due to its copper coordination, which is correct and expected. A white, milky, or particulate-containing solution in any other compound warrants investigation before use. Our reconstitution guide covers troubleshooting in detail.

The minimum standard for a credible research peptide supplier: lot-specific COA with your order (not a generic document), HPLC purity ≥98% with the chromatogram visible, mass spectrometry identity confirmation, and independent third-party testing (not in-house). Beyond documentation, look for clear research-use-only labeling, transparent communication about what the compounds are and are not, and a verifiable physical address or business registration. Suppliers who cannot provide a lot-specific COA on request, who advertise research peptides with human use framing, or who make unverifiable pharmaceutical claims are not meeting the credibility standard serious research requires.

All compounds ship as lyophilized powder in sealed glass vials. Lyophilized peptides are stable at ambient temperature during standard shipping durations — refrigerated shipping is not required for sealed lyophilized vials. Orders are packaged to prevent breakage and light exposure during transit. For shipping timelines and specific policies, see our shipping policy.

Yes. Every CoreVionRX order includes a lot-specific Certificate of Analysis documenting HPLC purity and mass spectrometry identity for the specific batch in your order. The COA is tied to the lot number of your shipment — it is not a generic marketing document used across all orders. If you need the COA for a previous order, contact us through the contact page with your order number and we will provide it.

If there is a documented discrepancy between the COA we provide and independent testing you conduct, contact us. We stand behind the documentation standards we publish. For order issues, damaged shipments, or other concerns, see our refund policy or reach us directly through the contact page.

BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic peptide derived from a protein found in gastric juice, studied primarily for its effects on tissue repair, growth factor signaling, and angiogenesis in preclinical models. TB-500 is a synthetic analog of Thymosin Beta-4, a 43-amino-acid protein involved in actin regulation, cell migration, and tissue remodeling. Both are studied in injury and repair research contexts but through entirely different biological pathways. They are often studied in combination in dual-peptide protocols because their mechanisms are complementary rather than redundant. See the BPC-157 research overview and TB-500 research overview for compound-specific documentation.

CJC-1295 with DAC contains a Drug Affinity Complex — a maleimide group that covalently binds albumin in plasma, dramatically extending the compound’s half-life from approximately 30 minutes to several days. CJC-1295 without DAC (also called Modified GRF 1-29) produces an acute GH pulse within the first hour and clears. The choice between them determines your dosing paradigm: without DAC for pulsatile GH stimulation research, with DAC for sustained elevation research. These are distinct compounds with different pharmacokinetics — receiving the wrong one is a meaningful experimental error. The CJC-1295 DAC research overview covers the DAC mechanism and its implications for COA verification.

The GLOW blend contains GHK-Cu (50mg), BPC-157 (10mg), and TB-500 (10mg) — a 70mg total multi-compound lyophilized blend combining a copper peptide with two tissue-repair research peptides. The KLOW blend is an 80mg four-compound blend containing GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg). Both blends ship as a single lyophilized vial with a COA covering all components. Reconstitute as a single preparation — the components do not require separate handling.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide, and dissolves readily in bacteriostatic water or sterile water. Unlike lyophilized peptides, NAD+ does not require special reconstitution technique — it dissolves quickly without the risk of aggregation from mechanical disruption. The more important consideration for NAD+ is solution stability: reconstituted NAD+ degrades faster in solution than most peptides, particularly at room temperature and under light exposure. Prepare fresh solutions as needed rather than storing reconstituted NAD+ for extended periods. See the NAD+ research overview for storage and handling specifics.

Each compound in the CoreVionRX catalog has a dedicated research overview page covering: what the compound is and its research context, primary mechanisms studied, purity and verification standards specific to that compound, storage and handling protocol, and sourcing documentation. Browse by compound on the research catalog, or access individual compound pages directly: BPC-157, TB-500, Ipamorelin, GHK-Cu, Semax, and more. The research blog covers mechanisms, quality verification, and lab protocols in additional depth.

Research-use-only compounds are sold exclusively for in vitro laboratory research and preclinical studies. They are not approved by the FDA or equivalent regulatory bodies for human or animal therapeutic use. In the United States, it is legal to purchase, possess, and use research chemicals for legitimate scientific research purposes. These compounds are not controlled substances. The “research use only” designation is an industry-standard designation that reflects the regulatory status of these materials — they exist in a distinct legal category from pharmaceutical drugs and are governed by different rules. CoreVionRX sells exclusively to researchers for laboratory use and does not support or facilitate any other use.

In the United States, research peptides are legal to purchase for legitimate research purposes. They are not scheduled substances under the Controlled Substances Act. Some specific compounds have different regulatory status in different countries — researchers outside the United States should verify the regulatory status of specific compounds in their jurisdiction before ordering. CoreVionRX ships within the United States. All products are labeled research-use-only and are not intended for human or animal consumption.

No. CoreVionRX compounds are sold exclusively for in vitro laboratory research and preclinical studies. They are not approved for human or animal use, are not sterile injectables, and have not undergone the clinical safety and efficacy testing required for human pharmaceutical use. They are not intended for, and must not be used for, human or animal consumption in any form. This is not a legal disclaimer — it is an accurate description of what these products are and what they are tested and qualified for.